Business Context and Reporting Period
Company: Revelation Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 16, 2022
Reporting Period: The filing announces financial results for the three months ended March 31, 2022.
Key Financial Metrics
The provided text is a cover sheet for a Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It solely serves to notify the SEC of the issuance of a press release containing the Q1 2022 results.
Guidance, Outlook, and Risks
Management Commentary: The registrant issued a press release on May 16, 2022, detailing results for the quarter ended March 31, 2022.
Legal Disclaimer: The information in Item 2.02 and the attached press release is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Risks/Contingencies: No specific risks or contingencies are detailed in this cover document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 16, 2022) for actual revenue, net loss, and cash position figures.
- Verify the company's status as an Emerging Growth Company (indicated as checked in the filing).
- Confirm the trading symbols: REVB (Common Stock), REVBW (Warrants), and REVBU (Units).
- Note that the financial data in the press release is not legally "filed" for liability purposes under Section 18 of the Exchange Act.